- RecruitingPHASE1, PHASE2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to usual treatment. It checks how safe they are, body reactions, and early signs of how well they might work.
For: Multiple MyelomaUnited States · Canada · Norway - Active not recruitingPHASE3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
This study is for adults with a type of blood cancer called follicular lymphoma, which has come back or isn't responding to treatment. It compares a new drug (Tazemetostat) with existing treatments to see if it's safe and helps people live longer without their cancer getting worse.
For: Relapsed/Refractory Follicular Lymphoma · Follicular Lymphoma · Refractory Follicular LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
This study is looking into a new treatment for advanced bladder cancer. It combines two drugs, tazemetostat and pembrolizumab, to see if they work better together. Doctors want to find the safest dose and understand how well this combination fights the cancer.
For: Locally Advanced Urothelial Carcinoma · Metastatic Urothelial Carcinoma · Stage III Bladder Cancer AJCC v8United States · Canada